Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589728486> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2589728486 endingPage "10526" @default.
- W2589728486 startingPage "10526" @default.
- W2589728486 abstract "10526 Background: We have recently developed a standardized system and defined cutoffs for assessment of molecular tumor subtype based on RNA expression of ESR1 and HER2 in FFPE tissue. (Müller et al. Diagn Mol Pathol 2011). Furthermore we described intratumoral and stromal lymphocytes as well as lymphocyte-predominant breast cancer (LPBC) as new predictors of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) (Denkert et al. J Clin Oncol 2010). Methods: The PREDICT substudy of the GeparQuinto trial (von Minckwitz et al. SABCS 2010) included a prospective independent validation of these 5 markers. RNA was extracted from 192 HER2neg FFPE breast cancer core biopsies using a fully-automated robot-based system. Expression of ESR1 and HER2 mRNA as well as control genes was determined by quantitative RT-PCR using predefined cutoffs. Test results were available in all cases before the patient underwent surgery. Results: 112 luminal tumors and 80 triple-negative (TNBC) tumors were defined by RNA-based subtyping. pCR rate was 40% in TNBC compared to 7.1% in luminal tumors. TNBC was predictive for response to NACT in logistic regression analysis (p<0.001) with an OR of 8.67 (95%CI [3.72-20.2]). LPBC had a pCR rate of 41%, compared to 14% for non-LPBC tumors (p<0.01). Intratumoral lymphocytes (p=0.005), stromal lymphocytes (p<0.005) and LPBC (p<0.005) were predictive for pCR in univariate logistic regression analysis. TNBC were more likely to contain an increased lymphocytic infiltrate compared to luminal tumors (p=0.001). Conclusions: This is the first report of a validated diagnostic test for mRNA based molecular subtyping. Distinct molecular subgroups according to the predefined cutoffs showed statistically significant different pCR rates. This standardized approach might be helpful to reliably define TNBCs as target population for clinical trials investigating new agents." @default.
- W2589728486 created "2017-03-03" @default.
- W2589728486 creator A5003665481 @default.
- W2589728486 creator A5003802011 @default.
- W2589728486 creator A5007647646 @default.
- W2589728486 creator A5008672227 @default.
- W2589728486 creator A5011410319 @default.
- W2589728486 creator A5018297283 @default.
- W2589728486 creator A5027184783 @default.
- W2589728486 creator A5030093893 @default.
- W2589728486 creator A5033698551 @default.
- W2589728486 creator A5041952632 @default.
- W2589728486 creator A5052454978 @default.
- W2589728486 creator A5056938516 @default.
- W2589728486 creator A5057181684 @default.
- W2589728486 creator A5087559224 @default.
- W2589728486 creator A5089035898 @default.
- W2589728486 date "2011-05-20" @default.
- W2589728486 modified "2023-09-26" @default.
- W2589728486 title "RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy." @default.
- W2589728486 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.10526" @default.
- W2589728486 hasPublicationYear "2011" @default.
- W2589728486 type Work @default.
- W2589728486 sameAs 2589728486 @default.
- W2589728486 citedByCount "2" @default.
- W2589728486 countsByYear W25897284862013 @default.
- W2589728486 countsByYear W25897284862018 @default.
- W2589728486 crossrefType "journal-article" @default.
- W2589728486 hasAuthorship W2589728486A5003665481 @default.
- W2589728486 hasAuthorship W2589728486A5003802011 @default.
- W2589728486 hasAuthorship W2589728486A5007647646 @default.
- W2589728486 hasAuthorship W2589728486A5008672227 @default.
- W2589728486 hasAuthorship W2589728486A5011410319 @default.
- W2589728486 hasAuthorship W2589728486A5018297283 @default.
- W2589728486 hasAuthorship W2589728486A5027184783 @default.
- W2589728486 hasAuthorship W2589728486A5030093893 @default.
- W2589728486 hasAuthorship W2589728486A5033698551 @default.
- W2589728486 hasAuthorship W2589728486A5041952632 @default.
- W2589728486 hasAuthorship W2589728486A5052454978 @default.
- W2589728486 hasAuthorship W2589728486A5056938516 @default.
- W2589728486 hasAuthorship W2589728486A5057181684 @default.
- W2589728486 hasAuthorship W2589728486A5087559224 @default.
- W2589728486 hasAuthorship W2589728486A5089035898 @default.
- W2589728486 hasConcept C121608353 @default.
- W2589728486 hasConcept C126322002 @default.
- W2589728486 hasConcept C142724271 @default.
- W2589728486 hasConcept C143998085 @default.
- W2589728486 hasConcept C144301174 @default.
- W2589728486 hasConcept C2777701055 @default.
- W2589728486 hasConcept C2778326572 @default.
- W2589728486 hasConcept C38180746 @default.
- W2589728486 hasConcept C530470458 @default.
- W2589728486 hasConcept C71924100 @default.
- W2589728486 hasConceptScore W2589728486C121608353 @default.
- W2589728486 hasConceptScore W2589728486C126322002 @default.
- W2589728486 hasConceptScore W2589728486C142724271 @default.
- W2589728486 hasConceptScore W2589728486C143998085 @default.
- W2589728486 hasConceptScore W2589728486C144301174 @default.
- W2589728486 hasConceptScore W2589728486C2777701055 @default.
- W2589728486 hasConceptScore W2589728486C2778326572 @default.
- W2589728486 hasConceptScore W2589728486C38180746 @default.
- W2589728486 hasConceptScore W2589728486C530470458 @default.
- W2589728486 hasConceptScore W2589728486C71924100 @default.
- W2589728486 hasIssue "15_suppl" @default.
- W2589728486 hasLocation W25897284861 @default.
- W2589728486 hasOpenAccess W2589728486 @default.
- W2589728486 hasPrimaryLocation W25897284861 @default.
- W2589728486 hasRelatedWork W1999960801 @default.
- W2589728486 hasRelatedWork W2091020218 @default.
- W2589728486 hasRelatedWork W2365364931 @default.
- W2589728486 hasRelatedWork W2418638721 @default.
- W2589728486 hasRelatedWork W3135028047 @default.
- W2589728486 hasRelatedWork W3160736738 @default.
- W2589728486 hasRelatedWork W3207434196 @default.
- W2589728486 hasRelatedWork W377899687 @default.
- W2589728486 hasRelatedWork W4220726198 @default.
- W2589728486 hasRelatedWork W4311801813 @default.
- W2589728486 hasVolume "29" @default.
- W2589728486 isParatext "false" @default.
- W2589728486 isRetracted "false" @default.
- W2589728486 magId "2589728486" @default.
- W2589728486 workType "article" @default.